PDS Biotechnology Corporation

NASDAQ:PDSB

Biotechnology

Healthcare
$0.92 +1.21%

+$0.01 today

Market cap
$51.58M
Beta
1.56
P/E (TTM)
-1.5
EPS (TTM)
-$0.60
52W Low $0.51High $1.67

Volume 5.25M

Average 1.04M

PDSB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

PDS Biotechnology CorporationNASDAQ: PDSB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow shrinks to $0

Q1 FY2026 stock-based compensation was $0, compared with $1.25M a year earlier. Trailing-twelve-month stock-based compensation was -$1.79B. Over 3 fiscal years it compounded at +824.6% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$448.35M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$4.11B+59866.3% YoY
LTMMar 2026
-$1.79B-27809.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+59866.3%——
3-year CAGR+824.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
4.11B USD
Year-over-year change
+59866.3%
4-year CAGR
+462.2%

Stock-Based Compensation vs competitors

How PDSB compares with its peers on the latest reported figures

  • PDSB's LTM Mar 2026 stock-based compensation of $1.79B is the largest of the 6 companies compared; the peer median is $1.48M.
  • Its year-over-year change of -27809.6% is the lowest of 6, against a peer median of -62.7%.
  • Over three fiscal years its annual growth of +824.6% compares with a peer median of +48.7%.
PDSB Competitors Peer median
Stock-Based Compensation for PDSB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDSBPDS Biotechnology CorporationLTM Mar 2026$1.79B -27809.6%+824.6%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026$11.67M +86.0%+523.5%—
XLOXilio Therapeutics, Inc.LTM Mar 2026$6.49M +5.8%-6.3%12.1%
ANVSAnnovis Bio, Inc.LTM Mar 2026$1.48M -62.7%+481.3%—
INMBINmune Bio, Inc.LTM Mar 2026$579K -107.3%+11.5%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$237K -98.0%+48.7%0.7%
Peer median (excluding PDSB) $1.48M-62.7%+48.7%6.4%

Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.92M)(40.85M)(42.94M)(37.61M)(34.5B)
Depreciation & Amortization5.36K8617.36K21.11K1.55B
Deferred Income Tax00000
Stock-Based Compensation4.11M5.2M7.61M6.85M4.11B
Change in Working Capital75.82K4.47M(199.28K)(5.75M)(382.97K)
Accounts Receivables00000
Inventory00000
Accounts Payables(105.82K)(90.12K)5.76M(5.3M)1.89M
Other Working Capital181.64K4.57M(5.96M)(453.77K)(2.27M)
Other Non-Cash Items241.03K5.47M1.87M1.46M1.08B
Operating Cash Flow(12.49M)(25.71M)(33.64M)(35.03M)(27.75B)
Capital Expenditures000(29K)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(29K)0
Debt Repayment025M(59.3K)(3.18M)(7.56M)
Common Stock Issued48.54M9.86M16.13M22.6M20.34M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities344.13K(568.87K)308.94K774.09K12.76B
Financing Cash Flow48.89M34.29M16.38M20.19M12.77B
Effect of Forex Changes00000
Net Change in Cash36.4M8.58M(17.26M)(14.87M)(14.98B)
Free Cash Flow(12.49M)(25.71M)(33.64M)(35.06M)(27.75B)

PDS Biotechnology Corporation

NASDAQ:PDSB

Intrinsic Alpha fair value

Locked

Current Price

$0.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.